

PAPER I

Errata

Paper I

The second subheading in the Discussion “PCB-153 concentrations and aAPC effects” should have been “PCB-153 concentrations and APC effects”.

Persistent Organic Pollutants in Norwegian Men from 1979 to 2007: Intraindividual Changes, Age-Period-Cohort Effects, and Model Predictions

Therese Haugdahl Nøst,^{1,2,3} Knut Breivik,^{4,5} Ole-Martin Fuskevåg,³ Evert Nieboer,^{1,6} Jon Øyvind Odland,¹ and Torkjel Manning Sandanger^{1,2}

¹Department of Community Medicine, University of Tromsø, Tromsø, Norway; ²NILU-Norwegian Institute for Air Research, Fram Centre, Tromsø, Norway; ³University Hospital of North Norway, Tromsø, Norway; ⁴NILU-Norwegian Institute for Air Research, Kjeller, Norway; ⁵Department of Chemistry, University of Oslo, Oslo, Norway; ⁶Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada

BACKGROUND: Longitudinal monitoring studies of persistent organic pollutants (POPs) in human populations are important to better understand changes with time and age, and for future predictions.

OBJECTIVES: We sought to describe serum POP time trends on an individual level, investigate age-period-cohort effects, and compare predicted polychlorinated biphenyl (PCB) concentrations to measured values.

METHODS: Serum was sampled in 1979, 1986, 1994, 2001, and 2007 from a cohort of 53 men in Northern Norway and analyzed for 41 POPs. Time period, age, and birth cohort effects were assessed by graphical analyses and mixed-effect models. We derived the predicted concentrations of four PCBs for each sampling year using the CoZMoMAN model.

RESULTS: The median decreases in summed serum POP concentrations (lipid-adjusted) in 1986, 1994, 2001, and 2007 relative to 1979 were -22%, -52%, -54%, and -68%, respectively. We observed substantial declines in all POP groups with the exception of chlordanes. Time period (reflected by sampling year) was the strongest descriptor of changes in PCB-153 concentrations. Predicted PCB-153 concentrations were consistent with measured concentrations in the study population.

CONCLUSIONS: Our results suggest substantial intraindividual declines in serum concentrations of legacy POPs from 1979 to 2007 in men from Northern Norway. These changes are consistent with reduced environmental exposure during these 30 years and highlight the relation between historic emissions and POP concentrations measured in humans. Observed data and interpretations are supported by estimates from the CoZMoMAN emission-based model. A longitudinal decrease in concentrations with age was evident for all birth cohorts. Overall, our findings support the relevance of age-period-cohort effects to human biomonitoring of environmental contaminants.

CITATION: Nøst TH, Breivik K, Fuskevåg OM, Nieboer E, Odland JØ, Sandanger TM. 2013. Persistent organic pollutants in Norwegian men from 1979 to 2007: intraindividual changes, age-period-cohort effects, and model predictions. *Environ Health Perspect* 121:1292–1298; <http://dx.doi.org/10.1289/ehp.1206317>

Introduction

The use of persistent organic pollutants (POPs) in agriculture and industry increased markedly beginning in the 1930s [Arctic Monitoring and Assessment Programme (AMAP) 2004]. As concerns for the detrimental effects of POPs on the environment and human health increased, measures to reduce or eliminate the production and use of POPs were initiated in many countries from the 1970s onward (AMAP 1998). Consequently, global emissions of legacy POPs have largely followed the same trends. Reduced use and emissions of legacy POPs were followed by declining POP concentrations in air and biota (e.g., Hung et al. 2010; Rigé et al. 2010), which has led to reduced human exposure. Accordingly, declining concentrations of most banned compounds have been reported in the few available human longitudinal POP studies (Hagmar et al. 2006; Hovinga et al. 1992; Høyer et al. 2000; Tee et al. 2003; Vo et al. 2008).

POP concentrations have frequently been reported to be positively associated with age

(Hardell et al. 2010; Rylander et al. 1997; Wolff et al. 2005) and to birth cohorts (Bjerregaard et al. 2001; Perry et al. 2005; Wolff et al. 2007) in human cross-sectional studies. In such studies, age and birth cohort effects are confounded (Glenn 2003; Quinn and Wania 2012). In longitudinal epidemiologic studies, age effects reflect differences in risk factors between age groups, period effects reflect temporal changes in factors that affect all individuals in a population, and birth cohort effects reflect generation-specific influences (Glenn 2003; Holford 1991; Palmore 1978). The interdependence of age, period, and cohort effects produces mutual confounding in time-trend studies. This has previously not been considered in empirical studies of POP time trends.

A person's lifetime environmental exposure to any POP (i.e., the intensity and duration of individual environmental exposure) depends on birth year relative to the time of peak environmental concentrations. Increasing age is associated with physiological changes (e.g., changes in body composition and

metabolism) and changes in dietary patterns that may influence both the intake and the elimination of POPs. Environmental exposures and dietary habits also differ among birth cohorts and contribute to differences in the duration and intensity of exposures to specific POPs. Finally, periodic patterns reflect changes in environmental POP concentrations related to historic emissions and environmental persistence, in addition to temporal trends in dietary intakes.

The present study was based on five repeated measurements of serum POPs concentrations during 1979–2007 in a cohort of 53 men from Northern Norway. Our primary aims were to describe intraindividual changes in POP concentrations and composition and to investigate age-period-cohort (APC) effects. In addition, we compared measured POPs concentrations and observed APC patterns to predictions based on the time-variant CoZMoMAN model (Breivik et al. 2010). Use of emission-based mechanistic modeling in combination with the unique empirical data available for the study population provides insight into the relationship between environmental emissions and observed concentrations in humans.

Subjects and Methods

Study population and subject selection. Five repeated population surveys in the Tromsø study (summarized by Jacobsen et al. 2012) took place in the municipality of Tromsø in Northern Norway, in 1979, 1986–1987 (hereafter referred to as 1986), 1994–1995

Address correspondence to T.H. Nøst, NILU-Norwegian Institute for Air Research, Fram Centre, NO-9296 Tromsø, Norway. Telephone: (47) 77750398. E-mail: zhn@nilu.no

Supplemental Material is available online (<http://dx.doi.org/10.1289/ehp.1206317>).

We are grateful to the study participants. We also thank K.M. Kanstad and J. Mathiassen for access to the Tromsø study samples and related information, and Unilab Analyse AS, Tromsø, Norway, for the contribution to the determination of lipids.

This project was supported by the Northern Norway Regional Health Authority, the Fram Centre, the Research Council of Norway, and the EU project ArcRisk (<http://www.arcrisk.eu>).

The authors declare they have no actual or potential competing financial interests.

Received: 26 November 2012; Accepted: 30 August 2013; Advance Publication: 5 September 2013; Final Publication: 1 December 2013.

(1994), 2001, and 2007–2008 (2007). Of 60 randomly selected men, 53 had sufficient sample volumes in ≥ 3 sampling years (11 missing samples were randomly distributed across sampling years). In total, the present analyses comprised 254 serum samples from 53 men. Birth year and body mass index information was extracted from questionnaires. The study was approved by the Regional Committees for Medical Research Ethics. Participation was voluntary and all participants provided informed consent. Serum samples were stored at -70°C until analysis.

Analytical methodology. All contaminant analyses were performed during 2011 at the laboratories of the Norwegian Institute for Air Research (NILU) and the University Hospital of Northern Norway (UNN). Serum samples were extracted and analyzed for polychlorinated biphenyls (PCBs) and organochlorine pesticides [chlordanes, hexachlorohexanes (HCHs), hexachlorobenzene (HCB), 1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)ethane (*p,p'*-DDT) and its metabolites (DDTs), and toxaphenes]. A complete list of the individual POPs is provided in Supplemental Material, Table S1.

Extraction and cleanup. Methods for extraction and cleanup were modified from Sandanger et al. (2003, 2007). We weighed serum samples [mean 0.92 g (range, 0.24–1.12 g)] and added 26 ^{13}C -labeled internal standards, deionized water saturated with ammonium sulfate (1 mL), methanol (2 mL), and hexane (6 mL) to the samples. Each serum mixture was vortexed and shaken for 1 hr. The samples were centrifuged (1,200 rpm, 6 min) in an Eppendorf 5702R centrifuge (Eppendorf, Hamburg, Germany), and the supernatant hexane was pipetted off. The extraction protocol was repeated with 6 mL of hexane, and the hexane supernatants were combined and evaporated to 0.5 mL in a heated vacuum evaporation unit. We performed subsequent cleanup using solid-phase extraction columns (Florisol, 1 g, deactivated) in an automated liquid handling system. Each column was prewashed with hexane/dichloromethane (DCM) (12 mL; 9:1 wt/wt) and hexane (12 mL) before the extract was applied. Analytes were subsequently eluted with hexane/DCM (12 mL; 9:1 wt/wt), evaporated to 0.2 mL, transferred to a GC-vial, further reduced to $\sim 30\ \mu\text{L}$ by gentle nitrogen flow, and recovery standard (octachloronaphthalene) was then added.

Instrumental analysis. Chlorinated pesticides (excluding DDTs) (1- μL injection volume) were analyzed on an Agilent 7890A gas chromatograph (GC) (Agilent Technologies Europe, Boeblingen, Germany) equipped with a 5975c mass spectrometer (MS) (instrumental details were described previously by Hansen et al. 2010). We operated the MS

in selected ion monitoring (SIM) and negative chemical ionization (NCI) modes at 160°C . All POPs were analyzed with the GC temperature program used by Hansen et al. (2010) with the exception of the toxaphenes, which were analyzed separately under the following conditions: 70°C (3 min), $25^{\circ}\text{C}\ \text{min}^{-1}$ to 180°C (0 min), and $15^{\circ}\text{C}\ \text{min}^{-1}$ to 280°C (5 min).

We analyzed PCBs and DDTs on the same GC as described above but with a Quattro Micro triple quadrupole MS (Waters Corporation, Manchester, UK). Injector settings, GC column, carrier gas, and the temperature program were as described above for pesticide analyses. The MS operated in MS/MS (MRM) mode with an electron ionization source at 220°C . Argon ($\sim 0.23\ \text{Pa}$) was the collision gas. Information regarding ion transitions has been published previously (Pitarch et al. 2007).

Lipid determination. Analyses of triglycerides, phospholipids, free cholesterol, and total cholesterol were determined enzymatically by Unilab Analyse AS, Tromsø, Norway, and a summed lipid concentration was calculated according to the equation proposed by Akins et al. (1989).

Quality assurance and sample integrity.

Quality control in POP and lipid analyses. To assess laboratory-derived sample contamination and method accuracy and reproducibility, we processed blanks ($n = 9$) and standard reference materials (SRMs) [SRM[®] 1958 ($n = 9$) and 1957 ($n = 9$), both from the National Institute of Standards and Technology, Gaithersburg, MD, USA] along with the samples. Results for SRMs indicated analytical uncertainties within $\pm 20\%$ of assigned values (within $\pm 5\%$ for many compounds). The NILU laboratory routinely participates in the international AMAP Ring Test for Persistent Organic Pollutants in Human Serum and has performed well (within $\pm 20\%$ of assigned values). Concomitantly, summed lipid concentrations in the test samples ($n = 10$) were within a 15% deviation from assigned values. [Ring test results are available from the Institut national de santé publique du Québec (2013).]

Mean recoveries of internal standards were 81%, 83%, 77%, 79%, and 56% for the 1979, 1986, 1994, 2001, and 2007 samples, respectively. The internal standard recovery for the 2007 samples was low in one sample preparation batch (53% of the 2007 samples); however, there was no association between recoveries and concentrations (data not shown). Recoveries were $< 30\%$ in three samples but were not excluded from statistical analyses because they did not constitute extreme observations nor did they deviate in model diagnostic plots. We rejected results when their isotopic mass ratios deviated by

$> 20\%$ from the quantification standards. PCB-138/163, PCB-47/49, and PCB-28/31 coeluted, and we summed their concentrations. The limits of detection (LODs) were software-generated and corresponded to signal-to-noise ratios of 3. Because consistent amounts of β -HCH and *oxy*-chlordane were measured in blanks, we subtracted mean blank concentrations for these compounds from all samples.

Estimation of desiccation and lipid degradation. To correct for spuriously high POP concentrations caused by evaporation during long-term storage, serum sodium (Na^+) was measured and used to adjust lipid and POP concentrations. In samples with Na^+ concentrations $> 165\ \text{mmol/L}$ (3% of samples), lipid and POP concentrations were adjusted by the ratio $[\text{Na}^+]_{\text{mean}}/[\text{Na}^+]_{\text{sample}}$ (Krieger et al. 1994). Na^+ determinations were conducted at UNN using an ion-selective electrode method.

Total cholesterol and triglycerides were measured previously and, after adjusting current results for desiccation, the past and current measurements deviated $< 10\%$ and correlations between the two measurements increased (data not shown).

Time-variant model simulations of PCBs in serum. Simulations of lipid-normalized serum concentrations of PCBs 118, 138, 153, and 180 for 1979, 1986, 1994, 2001, and 2007 were carried out using the time-variant multimedia mechanistic CoZMoMAN model (Breivik et al. 2010). Previous CoZMoMAN model predictions for PCB concentrations and their temporal changes in women were within the ranges of measured concentrations (Breivik et al. 2010; Quinn and Wania 2012). Simulations were performed assuming time-variant emission scenarios (Quinn et al. 2011). In general, model parameters were set as outlined by Breivik et al. (2010). Specifically, we assumed that trends and concentrations in the environment and food chains in Northern Norway are similar to the trends for Sweden and parts of Southeastern Norway that were used for model development, except for the dietary input parameters. We assumed that fish consumption in the population of older men from Northern Norway was higher than the original model input; therefore, we derived separate predictions based on average Norwegian fish consumption and three categories of higher fish consumption (for detailed information, see Supplemental Material, pp. 3–4 and Table S2). Model predictions for PCB-153 for the birth years 1930, 1935, 1940, and 1945 (within the range of birth years of the study subjects) were obtained, assuming that either all of the birth cohorts had equal fish consumption or that fish consumption differed among birth cohorts, with the earliest birth cohort consuming the most fish, and the latest cohort the least.

Data treatment and statistical methods. We performed statistical analyses using R, version 2.13.1 (R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was defined as $p < 0.05$. All POP results were lipid-adjusted and \log_e -transformed in the statistical analyses. We excluded three samples from 1979 with high ($> \text{median} + 2\text{SD}$) and three samples from 1994 with low lipid-adjusted concentrations ($< \text{median} - 2\text{SD}$) from statistical models in order to obtain the most appropriate model estimates; however, analyses including these samples and when performed on wet weight concentrations gave the same main results (data not shown). Lipid concentrations were missing for one sample, and thus the numbers of observations in the statistical analyses were 51, 51, 45, 48, and 52 for the five time points.

We calculated summed POP concentrations based on lipid-adjusted concentrations of compounds with $> 60\%$ detection; for values below LOD, we used the individual concentration estimates. Summary statistics for compounds with detection frequencies between 20% and 80% were calculated for

each sampling year using the Kaplan–Meier method with the NADA package for R according to Helsel (2005).

Spearman's ρ values were calculated for correlations. We used the Wilcoxon signed rank test to test differences in POP concentrations between sampling years and the Kruskal–Wallis rank sum test to test differences between birth year groups (categorized according to quartiles) in each sampling year.

We assessed APC effects for serum concentrations of PCB-153 using age and birth cohort groups categorized according to quartiles. We used mixed-effect models (lme4 package for R) that included a random slope for sampling year and subject-specific random terms (to allow subject-specific random variation) to estimate periodic changes in PCB-153 concentrations and potential age-specific and birth cohort-specific effects. Despite collinearity, models used to assess APC effects must include all three time parameters (Palmore 1978); therefore, we used mixed-effects models with two parameters modeled as fixed effects and the third modeled as a random effect (Ding et al.

2007). We also assessed body mass index as a fixed effect. Confidence intervals (CIs) for coefficients were obtained post hoc (glht in multcomp R package). We used Akaike's information criterion (AIC) to compare models, and the nonparametric Friedman's test to test differences across all measurements.

A graphical examination of APC effects for PCB-153 was carried out by plotting all six combinations of the three time factors according to Ahacic et al. (2012) to assess longitudinal patterns (i.e., concentrations according to birth cohort and sampling period or age), time-lag patterns (concentrations according to age and sampling period or birth cohort), or cross-sectional patterns (concentrations according to sampling period and age or birth cohort).

Results

Characteristics of study participants. Median ages at the first and last sampling were 43 and 71 years, respectively (Table 1). The median birth year was 1936 (range, 1925–1950). The number of subjects in each age and birth cohort quartile is listed in Supplemental Material, Table S3.

Intraindividual changes in POP concentrations. Serum POP concentrations in each sampling year are presented for selected compounds in Figure 1 (see Supplemental Material, Table S4 for complete data for all analyzed POPs). The median individual decreases in summed POP concentrations in 1986, 1994, 2001, and 2007 relative to the

Table 1. Descriptive age statistics of study participants measured in 1979, 1986, 1994, 2001, and 2007 (all male).

Age	1979 (n = 51)	1986 (n = 51)	1994 (n = 45)	2001 (n = 48)	2007 (n = 52)
Median	43	50	58	65	71
Minimum	29	36	44	51	57
Maximum	54	61	69	76	82




Figure 1. Concentrations (ng/g lipid, \log_e scale) of selected POPs analyzed in repeated serum samples of men ($n = 51, 51, 45, 48,$ and 52 in 1979, 1986, 1994, 2001, and 2007, respectively) from Northern Norway. p,p' -DDE, 1,1-dichloro-2,2-bis(p -chlorophenyl)ethylene. Parlar 50 represents toxaphenes, and *trans*-nonachlor the chlordanes. Boxes represent the 25th–75th percentiles, horizontal lines represent the median, whiskers indicate 1.5 times the length of the interquartile range above and below the 75th and 25th percentiles, respectively, and outliers are represented as data points.

* $p < 0.05$, and ** $p < 0.001$ for comparisons between pairs of consecutive sampling years.

median concentration in 1979 were -22% , -52% , -54% , and -68% , respectively. Substantial declines were observed for all POPs with the exception of chlordanes [e.g., *trans*-nonachlor (Figure 1)]. Overall, decreases were observed from 1979 in concentrations of HCHs, HCB, *c*-chlordane, DDTs, and most penta-chlorinated PCBs (PCBs 99, 101, 105, 118, and 123) and hexa-chlorinated PCBs (PCB 128, 141, 149, 153, and 167). Declining trends were exponential for many POPs, especially for *p,p'*-DDT ($R^2 = 0.78$ for fitted exponential trend line, data not shown). Concentrations of chlordanes (except *c*-chlordane), mirex, toxaphenes, and hepta- and octa-chlorinated PCBs (PCBs 170, 180, 187, and 194) initially increased from 1979 to 1986, and then declined in subsequent years. Concentration differences across all sampling years were significant for all POPs (Friedman's test, $p < 0.001$); however, the absolute differences in the concentrations of chlordanes were small (e.g., 47 and 45 ng/g lipid adjusted for *trans*-nonachlor in 1979 and 2007, respectively). Within individuals, the concentrations of most POPs were higher in 1979 than in 2007, but time trends varied among individuals, as shown for PCB-153 (Figure 2; individuals grouped according to birth year).

Relative contributions of individual POPs to summed POP concentrations (as a percentage) are shown in Figure 3. Clearly, 1,1-dichloro-2,2-bis(*p*-chlorophenyl)ethylene (*p,p'*-DDE); PCBs 153, 138/163, and 180; and HCB were the most prominent (67–73% of sum in the different sampling years). *p,p'*-DDE/*p,p'*-DDT ratios were 12, 20, 29, 41, and 55 for 1979, 1986, 1994, 2001, and 2007, respectively.

POP correlations across sampling years. The correlations of concentrations (lipid-adjusted) in any pair of consecutive sampling years increased across the study period for most compounds. Concentrations correlated significantly between 1986 and 1994, 1994 and 2001, and 2001 and 2007 for PCB-153 ($\rho = 0.72, 0.80,$ and 0.87 , respectively, all $p < 0.001$), and between all sampling years for *p,p'*-DDE ($\rho = 0.44, 0.79, 0.87,$ and 0.89 between 1979 and 1986, 1986, and 1994, 1994 and 2001, and 2001 and 2007, respectively, all $p < 0.002$).

Intercompound correlations. In 1979, correlations were strong ($\rho > 0.85$) between PCB-153 and *oxy*-chlordane, mirex, and PCBs 99, 118, 138/163, 156, 157, 167, 170, 180, 183, 187, 189, and 194. The correlations between PCB-153 and other POPs were also strong in the subsequent sampling years ($\rho > 0.85$; $n = 13, 8, 10,$ and 9 compounds for 1986, 1994, 2001, and 2007, respectively), yet slightly weaker over time.

Predicted PCB concentrations. Measured and predicted concentrations (nanograms

per gram lipid) of PCBs 118, 138, 153, and 180 from CoZMoMAN simulations for a 1935 birth cohort of men are presented in Supplemental Material, Figure S1 for the 5 sampling years according to four different assumptions regarding fish consumption. Model predictions were generally consistent with measured concentrations, especially for PCBs 153 and 180, but overestimated concentrations of PCB-118 and underestimated

concentrations of PCB-138. Predicted trends (assuming equal fish consumption among birth cohorts) for PCB-153 concentrations for men born in 1930, 1940, and 1945 (see Supplemental Material, Figure S2) showed similar trends among birth years.

Estimated APC effects on changes in PCB-153 concentrations. Estimates from mixed-effect models of PCB-153 concentrations in the different sampling years, with age, period,




Figure 2. Individual trend lines for PCB-153 serum concentrations (ng/g lipid) measured in 1979, 1986, 1994, 2001, and 2007 in 53 men from Northern Norway, according to birth year quartile. (A) 1925–1934, (B) 1934–1936, (C) 1936–1941, and (D) 1941–1950.




Figure 3. Relative contributions of individual POPs that accounted for $> 1\%$ of summed POPs in 1979 in serum from men ($n = 51, 51, 45, 48,$ and 52 in 1979, 1986, 1994, 2001, and 2007, respectively) in Northern Norway.

and birth cohort modeled as fixed predictors or as random effects (accounting for subject-specific variation) are shown in Table 2. The best fitting model included period and birth cohort as predictors, and age as a random effect. Estimates for the period effects (i.e., changes according to sampling year) were generally consistent among models. Including body mass index for all sampling years did not improve the model (data not shown). Additional models that specified interactions or nonlinear effects (as product or cubic terms, respectively) were not possible (they did not converge).

Figure 4 shows selected plots of a graphical examination of APC effects. The period effect is apparent as decreasing PCB-153 concentrations across the sampling years and as subjects aged (Figure 4A,B). Although differences in PCB-153 concentrations among birth cohort quartiles across sampling years were not significant for some sampling years (Figure 4A), the most recently born cohort (1941–1950) appeared to have the lowest concentrations, and the earliest cohort (1925–1934) had the highest. Within sampling years, concentrations increased with age and decreased in more recent birth cohorts (Figure 4C; see also Supplemental Material, Figure S3C). Finally, within age groups, concentrations decreased according to sampling period and birth year (see Supplemental Material, Figure S3A and B, respectively). Overall, the graphical examination suggests clear period effects and additional birth cohort effects, whereas age effects appear relatively weak. APC patterns based on predicted PCB-153 concentrations (Figure 4D–F; see also Supplemental Material,

Figure S3D–F) were generally consistent with patterns based on measured values.

Discussion

Intraindividual changes in POP concentrations from 1979 to 2007. Overall, our findings suggest that POP concentrations decreased during 1979–2007 in men from Northern Norway. Average summed POP concentrations in 2007 were one third of concentrations measured in 1979. The majority of POP concentrations declined from 1979, although median concentrations of some compounds peaked in 1986 (e.g., PCBs 170, 180, and 194). Peak PCB-153 concentrations were measured in 1979 and 1986, confirming this period as the years of highest human exposure, a feature which was also reproduced by CoZMoMAN (see Supplemental Material, Figure S1). We also observed large individual variability during these years, as could be expected.

The downward trends in serum concentrations likely reflect declining environmental concentrations due to reduced emissions during the same time period. This is in accordance with previous findings for environmental and human POP concentrations in Europe (AMAP 1998; Bignert et al. 1998). Our findings indicate that serum concentrations of DDTs peaked before PCBs, which is consistent with emission estimates for DDTs (Li and Macdonald 2005) and PCBs (Breivik et al. 2010). The delay in global emissions of PCB-containing products (e.g., transformers, capacitors) (Breivik et al. 2007). The declines of many POPs, especially *p,p'*-DDT, were

exponential and indicated nonlinear rates of decrease across the study period. The concentrations of some compounds were unchanged or decreased only slightly (chlordanes and mirex), emphasizing the need to include these compounds in monitoring studies. Correlations of POPs in any pair of consecutive sampling years became stronger during the study period, possibly due to reduced concentrations and reduced variability of exposures over time.

Our results suggest that regulatory measures to reduce the manufacture and use of POPs during the 1970s and 1980s had rapid impacts not only on environmental concentrations (AMAP 1998), but also on human exposures. Substantial reductions in human intake rates relative to elimination rates are suggested.

PCB-153 concentrations and aAPC effects.

Time period had the strongest influence on PCB-153 concentrations based on both the graphical examination and the mixed-effect analyses. Although the range of birth years (1925–1950) was relatively narrow, the mixed-effect analyses also suggested an additional influence of birth cohort. This may reflect differences in cumulative exposure and dietary patterns among birth cohorts, consistent with associations between PCB-153 and age or birth cohort that have been reported based on cross-sectional studies (Bjerregaard et al. 2001; Hardell et al. 2010; Perry et al. 2005; Rylander et al. 1997; Wolff et al. 2005, 2007).

Changes in dietary intakes (Quinn et al. 2012) and body mass (Wolff et al. 2007) must also be considered when evaluating time trends in human POP concentrations. When model simulations included the assumption

Table 2. Mixed-effect model estimates^a [coefficients (95% CIs)] of changes in PCB-153 concentrations (ng/g lipid) during 1979–2007 among 53 men from Northern Norway, with age, calendar period, and birth cohort as predictors.

Predictor	Model 1: period only (fixed effects)	Model 2: period and age (fixed effects)	Model 3: period and age (fixed effects) plus birth cohort (random effect) ^b	Model 4: period and birth cohort (fixed effects)	Model 5: period and birth cohort (fixed effects) plus age (random effect) ^b
Period^c					
1979	Referent	Referent	Referent	Referent	Referent
1986	51 (–68, 221)	72 (–69, 284)	82 (–71, 311)	67 (–98, 326)	22 (–104, 202)
1994	–85 (–156, 12)	–66 (–159, 73)	–82 (–175, 54)	–82 (–179, 62)	–117 (–191, –16)
2001	–95 (–163, –2)	–76 (–172, 74)	–93 (–189, 52)	–84 (–181, 57)	–119 (–194, –17)
2007	–160 (–210, –90)	–150 (–224, –30)	–175 (–245, –65)	–163 (–238, –52)	–190 (–251, –103)
Age (years)^d					
29–47	—	Referent	Referent	—	—
47–57	—	–32 (–122, 94)	–31 (–122, 94)	—	—
57–66	—	–35 (–138, 117)	–27 (–133, 126)	—	—
66–82	—	–24 (–144, 167)	–4 (–129, 184)	—	—
Birth cohort^e					
1925–1934	—	—	—	Referent	Referent
1934–1936	—	—	—	–73 (–210, 170)	–61 (–199, 173)
1936–1941	—	—	—	–24 (–180, 249)	–17 (–171, 244)
1941–1950	—	—	—	–139 (–246, 50)	–149 (–251, 26)
AIC ^f	154	157	176	151	137

All models included a subject-specific random term and a random slope for sampling year; age and birth cohort variables were divided into quartiles.

^aCoefficients are backtransformed from log-estimates of fixed effect variables and are in units of ng/g lipid. ^bVariables were added to models as random terms to allow for random variation in individuals. ^cCoefficients express change for PCB-153 concentrations (ng/g lipid) across sampling years, with 1979 as the reference period category. ^dCoefficients express change in PCB-153 concentrations (ng/g lipid) across age quartiles, with the youngest age group (29–47 years) as the reference category. ^eCoefficients express change in PCB-153 concentrations (ng/g lipid) across birth cohort quartiles with the oldest birth cohort group (1925–1934) as the reference category. ^fLower Akaike's information criterion numbers indicate better model fit when comparing models.

of higher fish consumption in earlier birth cohorts (in accordance with the available dietary information and intergenerational dietary differences in Quinn et al. 2012), we observed consistent patterns of predicted and observed PCB-153 concentrations according to birth cohort (Figure 4A,D). Although predictions were not based on individual dietary information, CoZMoMAN model estimates were consistent with observed birth cohort patterns. This supports the use of mechanistic modeling in hypothesis testing and illustrates that an understanding of temporal trends in emissions and of confounded time factors is relevant for POP monitoring studies.

Changes in relative concentrations of POPs.

The relative concentrations of POPs in human serum changed over time, both between and within POP groups. The majority of POPs evaluated were highly correlated with PCB-153 concentrations during all sampling years, supporting the use of PCB-153 as a marker compound for many legacy POPs, although it is important to note that correlations with PCB-153 concentrations weakened over time.

Proportions relative to the sum of all POPs decreased for *p,p'*-DDE (from 37% in 1979 to 21% in 2007) and increased for the sum of PCB 138, 153, and 180 (from 30% in 1979 to 44% in 2007). A steeper decline in concentrations for *p,p'*-DDE compared with PCB-153 has been reported previously based on human longitudinal studies (Hagmar et al. 2006; Hovinga et al. 1992; Vo et al. 2008). Because the *p,p'*-DDE/*p,p'*-DDT ratio is sensitive to recent exposure to *p,p'*-DDT (Anda et al. 2007), its increase from 12 in 1979 to 55 in 2007 suggests that exposure to *p,p'*-DDT was markedly reduced. The relative contribution of PCBs (and especially the higher-chlorinated congeners) to summed POPs increased, and thus PCBs might be expected to dominate future organochlorine POP burdens. Overall, the relative changes in POP concentrations may be explained by differences in emission histories, environmental persistence, exposure sources, and elimination rates.

Comparisons to other longitudinal studies.

Clearly, age distribution and time of sampling relative to historic POP emissions must

be considered when comparing longitudinal POP trends. The concentrations and temporal changes in PCB-153, *p,p'*-DDE, and HCB in our study population were similar to findings for younger Swedish men sampled in 1991 and 2001 (Hagmar et al. 2006). Measured concentrations were lower and peaked later in our study population than POPs concentrations measured in two longitudinal cohorts in the Great Lakes area [Hovinga et al. 1992 (sampled in 1982 and 1989); Tee et al. 2003 (sampled in 1980, 1990, and 1994)]. These similarities and differences may reflect geographical differences in environmental exposures during the same time period, in addition to different dietary patterns.

Evaluation of time-variant model predictions. We challenged the CoZMoMAN mechanistic model with observations in order to evaluate its performance. Overall, the model's predictions were in reasonable agreement with temporal changes in median measured concentrations from 1979 to 2007, especially for PCB-153. The observed overestimation of PCB-118 by the CoZMoMAN model has




Figure 4. APC plots showing observed (A–C) and predicted serum PCB-153 concentrations (D–F, using the CoZMoMAN model assuming higher fish consumption in earlier birth cohorts). A and D show longitudinal variation among birth cohorts according to sampling period, B and E show longitudinal variation among birth cohorts according to age quartile (Q), and C and F cross-sectional variation among sampling periods according to age quartile. Data points indicate ng/g lipid-adjusted concentrations (median concentrations are displayed in A–C). Differences between birth cohorts in A were significant in 1986 and 2007 (Kruskal–Wallis rank sum test, $p < 0.05$).

also been reported by Czub and McLachlan (2004), who suggested that it could be due to an incorrect assumption of zero metabolism of this congener in humans. The coelution of PCB-138 and PCB-163 in chromatograms is likely the reason for the apparent underestimation of PCB-138. The model did predict an initial increase of PCB-180 during the early 1980s consistent with our empirical results, although the observed decline afterwards was slightly steeper than predicted.

Study limitations. Although statistical approaches to APC effects have been much discussed in the literature, no consensus has been reached (Glenn 2003). Currently, suitable *p*-values in mixed-effect models cannot be calculated in the statistical software. Potential interactions between the time factors could not be considered in the mixed-effect model analysis, and our ability to examine APC effects was limited by the small numbers of men in some age groups.

Individual dietary information was not available for the model parameterization; therefore, we used estimates of average and high fish consumption in Norwegian populations to reflect the potential range of fish consumption in the study population instead.

Conclusions

Longitudinal declines in legacy POPs in serum samples from Norwegian men during 1979–2007 are consistent with reduced environmental exposures in this period. Our adaptation of methods to assess APC effects based on biomonitoring data is novel and suggests that calendar time (i.e., period effects) had a major influence on observed concentrations, although birth cohort differences were also indicated. Predicted concentrations and time trends for PCB-153 were consistent with those measured. The use of APC analysis and emission-based modeling in human biomonitoring enhances our understanding of the relationship between temporal trends in human POP burdens and historical emissions.

REFERENCES

Ahacic K, Kennison RF, Kåreholt I. 2012. Changes in sobriety in the Swedish population over three decades: age, period or cohort effects? *Addiction* 107:748–755.

Akins JR, Waldrep K, Bernert Jr JT. 1989. The estimation of total serum lipids by a completely enzymatic 'summation' method. *Clin Chim Acta* 184(3):219–226.

AMAP (Arctic Monitoring and Assessment Programme). 1998. AMAP Assessment Report: Arctic Pollution Issues. Oslo, Norway:AMAP. Available: <http://www.amap.no/documents/doc/amap-assessment-report-arctic-pollution-issues/68> [accessed 17 September 2013].

AMAP (Arctic Monitoring and Assessment Programme). 2004.

AMAP Assessment 2002: Persistent Organic Pollutants in the Arctic. Oslo, Norway:AMAP. Available: <http://www.amap.no/documents/download/1159> [accessed 17 September 2013].

Anda EE, Nieboer E, Dudarev AA, Sandanger TM, Odland JØ. 2007. Intra- and intercompartmental associations between levels of organochlorines in maternal plasma, cord plasma and breast milk, and lead and cadmium in whole blood, for indigenous peoples of Chukotka, Russia. *J Environ Monit* 9(8):884–893.

Bignert A, Olsson M, Persson W, Jensen S, Zakrisson S, Litzén K, et al. 1998. Temporal trends of organochlorines in Northern Europe, 1967–1995. Relation to global fractionation, leakage from sediments and international measures. *Environ Pollut* 99(2):177–198.

Bjeregard P, Dewailly E, Ayotte P, Pars T, Ferron L, Mulvad G. 2001. Exposure of Inuit in Greenland to organochlorines through the marine diet. *J Toxicol Environ Health A* 62:69–81.

Breivik K, Czub G, McLachlan MS, Wania F. 2010. Towards an understanding of the link between environmental emissions and human body burdens of PCBs using CoZMoMAN. *Environ Int* 36(1):85–91.

Breivik K, Sweetman A, Pacyna JM, Jones KC. 2007. Towards a global historical emission inventory for selected PCB congeners—a mass balance approach: 3. An update. *Sci Total Environ* 377(2–3):296–307.

Czub G, McLachlan MS. 2004. A food chain model to predict the levels of lipophilic organic contaminants in humans. *Environ Toxicol Chem* 23(10):2356–2366.

Ding J, Kritchevsky SB, Newman AB, Taaffe DR, Nicklas BJ, Visser M, et al. 2007. Effects of birth cohort and age on body composition in a sample of community-based elderly. *Am J Clin Nutr* 85(2):405–410.

Glenn ND. 2003. Distinguishing age, period, and cohort effects. In: *Handbook of the Life Course* (Mortimer JT, Shanahan MJ, eds). New York:Kluwer Academic/Plenum Publishers, 465–476.

Hagmar L, Wallin E, Vessby B, Jönsson BAG, Bergman Å, Rylander L. 2006. Intra-individual variations and time trends 1991–2001 in human serum levels of PCB, DDE and hexachlorobenzene. *Chemosphere* 64(9):1507–1513.

Hansen S, Nieboer E, Odland JØ, Wilsgaard T, Veyhe AS, Sandanger TM. 2010. Levels of organochlorines and lipids across pregnancy, delivery and postpartum periods in women from Northern Norway. *J Environ Monit* 12:2128–2137.

Hardell E, Carlberg M, Nordström M, van Bavel B. 2010. Time trends of persistent organic pollutants in Sweden during 1993–2007 and relation to age, gender, body mass index, breast-feeding and parity. *Sci Total Environ* 408(20):4412–4419.

Helsel RD. 2005. *Nondetects and Data Analysis. Statistics for Censored Environmental Data*. Hoboken, NJ:Wiley Interscience.

Holford TR. 1991. Understanding the effects of age, period, and cohort on incidence and mortality rates. *Annu Rev Public Health* 12(1):425–457.

Hovinga ME, Sowers MF, Humphrey HEB. 1992. Historical changes in serum PCB and DDT levels in an environmentally-exposed cohort. *Arch Environ Contam Toxicol* 22(4):362–366.

Høyer AP, Jørgensen T, Grandjean P, Hartvig HB. 2000. Repeated measurements of organochlorine exposure and breast cancer risk (Denmark). *Cancer Causes Control* 11(2): 177–184.

Hung H, Kallenborn R, Breivik K, Su Y, Brorström-Lundén E, Olafsdottir K, et al. 2010. Atmospheric monitoring of organic pollutants in the Arctic under the Arctic Monitoring and Assessment Programme (AMAP): 1993–2006. *Sci Total Environ* 408(15):2854–2873.

Institut national de santé publique du Québec. 2013. AMAP Ring Test for Persistent Organic Pollutants in Human Serum. Available: <http://www.inspq.qc.ca/ctq/paqe/amap/rapports.asp?Page=2c&partie=2&Lg=en&PCI=6> [accessed 12 September 2013].

Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. 2012. Cohort profile: the Tromsø Study. *Int J Epidemiol* 41(4):961–967.

Krieger N, Wolff MS, Hiatt RA, Rivera M, Vogelman J, Orentreich N. 1994. Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. *J Natl Cancer Inst* 86(8):589–599.

Li Y, Macdonald R. 2005. Sources and pathways of selected organochlorine pesticides to the Arctic and the effect of pathway divergence on HCH trends in biota: a review. *Sci Total Environ* 342(1):87–106.

Palmore E. 1978. When can age, period, and cohort be separated? *Soc Forces* 57(1):282–295.

Perry MJ, Ouyang F, Korrick S, Venners SA, Altshul L, Xu X, et al. 2005. Body mass index and serum 1,1,1-trichloro-2,2-bis(p-chlorophenyl) ethane in nulliparous Chinese women. *Cancer Epidemiol Biomarkers Prev* 14(10):2433–2438.

Pitarch E, Medina C, Portolés T, López FJ, Hernández F. 2007. Determination of priority organic micro-pollutants in water by gas chromatography coupled to triple quadrupole mass spectrometry. *Anal Chim Acta* 583(2):246–258.

Quinn CL, Armitage JM, Breivik K, Wania F. 2012. A methodology for evaluating the influence of diets and intergenerational dietary transitions on historic and future human exposure to persistent organic pollutants in the Arctic. *Environ Int* 49:83–91.

Quinn CL, Wania F. 2012. Understanding differences in the body burden—age relationships of bioaccumulating contaminants based on population cross-sections versus individuals. *Environ Health Perspect* 120:554–559; doi:10.1289/ehp.1104236.

Quinn CL, Wania F, Czub G, Breivik K. 2011. Investigating intergenerational differences in human PCB exposure due to variable emissions and reproductive behaviors. *Environ Health Perspect* 119:641–646; doi:10.1289/ehp.1002415.

Rigét F, Bignert A, Braune B, Stow J, Wilson S. 2010. Temporal trends of legacy POPs in Arctic biota, an update. *Sci Total Environ* 408(15):2874–2884.

Rylander L, Dyrreberg E, Strömberg U, Östman C, Hagmar L. 1997. The impact of age, lactation and dietary habits on PCB in plasma in Swedish women. *Sci Total Environ* 207(1):55–61.

Sandanger TM, Brustad M, Lund E, Burkow IC. 2003. Change in levels of persistent organic pollutants in human plasma after consumption of a traditional northern Norwegian fish dish—mølje (cod, cod liver, cod liver oil and hard roe). *J Environ Monit* 5(1):160–165.

Sandanger TM, Sinotte M, Dumas P, Marchand M, Sandau CD, Pereg D, et al. 2007. Plasma concentrations of selected organobromine compounds and polychlorinated biphenyls in postmenopausal women of Québec, Canada. *Environ Health Perspect* 115:1429–1434; doi:10.1289/ehp.10303.

Tee PG, Sweeney AM, Symanski E, Gardiner JC, Gasior DM, Schantz SL. 2003. A longitudinal examination of factors related to changes in serum polychlorinated biphenyl levels. *Environ Health Perspect* 111:702–707; doi:10.1289/ehp.5866.

Vo TT, Gladen BC, Cooper GS, Baird DD, Daniels JL, Gammon MD, et al. 2008. Dichlorodiphenyldichloroethane and polychlorinated biphenyls: intraindividual changes, correlations, and predictors in healthy women from the southeastern United States. *Cancer Epidemiol Biomarkers Prev* 17(10):2729–2736.

Wolff MS, Anderson HA, Britton JA, Rothman N. 2007. Pharmacokinetic variability and modern epidemiology—the example of dichlorodiphenyltrichloroethane, body mass index, and birth cohort. *Cancer Epidemiol Biomarkers Prev* 16(10):1925–1930.

Wolff MS, Britton JA, Teitelbaum SL, Eng S, Deych E, Ireland K, et al. 2005. Improving organochlorine biomarker models for cancer research. *Cancer Epidemiol Biomarkers Prev* 14(9):2224–2236.

SUPPLEMENTAL MATERIAL

Persistent Organic Pollutants in Norwegian Men from 1979 to 2007: Intraindividual Changes, Age–Period–Cohort Effects, and Model Predictions

Therese Haugdahl Nøst,^{1,2,3} Knut Breivik,^{4,5} Ole-Martin Fuskevåg,³ Evert Nieboer,^{1,6} Jon Øyvind Odland,¹ and Torkjel Manning Sandanger^{1,2}

¹Department of Community Medicine, University of Tromsø, Tromsø, Norway; ²NILU-Norwegian Institute for Air Research, Fram Centre, Tromsø, Norway; ³University Hospital of North Norway, Tromsø, Norway; ⁴NILU-Norwegian Institute for Air Research, Kjeller, Norway; ⁵Department of Chemistry, University of Oslo, Oslo, Norway; ⁶Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.

Table of contents:

Supplemental Material, Table S1	Page 2
Supplemental Material, Information on dietary parameters used in CoZMoMAN modeling	Page 3
Supplemental Material, Table S2	Page 4
Supplemental Material, Table S3	Page 5
Supplemental Material, Table S4	Page 6
Supplemental Material, Figure S1	Page 8
Supplemental Material, Figure S2	Page 9
Supplemental Material, Figure S3	Page 10
Supplemental Material, References	Page 11

Supplemental Material, Table S1: List of compounds analyzed in blood samples.

Analyzed compounds	Abbreviation or IUPAC No.
Polychlorinated biphenyls (PCBs)	Congeners 18, 28/31, 33, 47/49, 52, 99, 101, 105, 118, 123, 128, 138/163, 141, 149, 153, 156, 157, 167, 170, 180, 183, 187, 189, 194
Hexachlorocyclohexanes (HCHs)	α -HCH, β -HCH, γ -HCH
Hexachlorobenzene	HCB
Chlordanes (CHLs)	<i>trans</i> - and <i>cis</i> -Chlordane, <i>oxy</i> -Chlordane, <i>trans</i> - and <i>cis</i> -Nonachlor
Mirex	
DDT and metabolites (DDTs)	1,1,1-trichloro-2,2-bis(<i>p</i> -chlorophenyl)ethane (<i>p,p'</i> -DDT) 1,1,1-trichloro-2-(<i>o</i> -chlorophenyl)-2-(<i>p</i> -chlorophenyl)ethane (<i>o,p'</i> -DDT) 1,1-dichloro-2,2-bis(<i>p</i> -chlorophenyl)ethene (<i>p,p'</i> -DDE) 1,1-dichloro-2-(<i>o</i> -chlorophenyl)-2-(<i>p</i> -chlorophenyl)ethene (<i>o,p'</i> -DDE) 1,1-dichloro-2,2-bis(<i>p</i> -chlorophenyl)ethane (<i>p,p'</i> -DDD) 1,1-dichloro-2-(<i>o</i> -chlorophenyl)-2-(<i>p</i> -chlorophenyl)ethane (<i>o,p'</i> -DDD)
Toxaphenes	Parlar 26 (B8–1413) and 50 (B9–1679)

Supplemental Material, Information on dietary input parameters used in CoZMoMAN.

The original description of dietary habits is based on the food consumption of the Swedish population (Czub and McLachlan 2004). Specifically, scenarios for the ingestion of fish, beef and dairy products were developed as a function of time from 1930 onwards. However, dietary habits of the current study population (i.e., men in Northern Norway) are likely to differ from the Swedish population with respect to fish consumption in particular. While historical dietary information from study subjects were insufficient, information on fish consumption in the Norwegian population is only available for the years after 1995 (Norwegian Directorate of Health 2010). While the general Swedish population eats fish 1.7 times/week, the general Norwegian population does so 2.3 times/week (Bergsten 2004). Most detailed information on fish consumption in the Norwegian population was available for 2000, and the dietary input to CoZMoMAN reflected this information by adjusting the original time-variant dietary parameterization to the numeric information for year 2000 (see Table S2: average fish consumption scenario for Norway (FC_{avr})).

An even higher rate of fish consumption was expected for the study population, compared to the general Norwegian population. High age, male sex and living in Northern Norway are all factors associated with high fish consumption (Alexander et al. 2006; Bergsten 2004; Johansson and Solvoll 1999). Simulations were therefore carried out based on four different scenarios for fish intake, representing the average Norwegian fish intake (as detailed above), as well as for three additional scenarios representing increased consumption of fish (FC1-FC3, see Table S2).

The highest fish consumption category (FC3) data were obtained by adjusting the fish consumption to a 95% percentile of total daily fish intake in 2000 (Bergsten 2004) (see Table S2), with a corresponding reduction in the intake of meat. Two additional categories between the average Norwegian fish intake and the highest were calculated (see Table S2).

Furthermore, the proportion of fish intake comprised of lean fish is high in the Norwegian population (2/3 of all fish consumption) (Alexander et al. 2006) and the herring/cod ratio used as a fat fish/lean fish indication in the model was consequently changed from 0.75/0.25 in the Swedish dietary parameters to 0.35/0.65 for the study population. Meat consumption was adjusted corresponding to changes in fish consumption in all categories. Consumption of dairy products in the study population as a function of time was assumed to be similar to that of the Swedish population.

In model simulations presented in Figure 4 and Supplemental Material, Figure S3, the fish consumption categories for the birth cohorts 1930, 1935, 1940 and 1945 were assumed to be F3, F2, F1 and F_{avr} , respectively.

Supplemental Material, Table S2: Fish consumption categories used in CoZMoMAN.

Fish consumption category	Abbreviation	Original CoZMoMAN parameterization (g ww/day in 2000)	In this article (g ww/day in 2000)
Average	FC_{avr}	92	124
Higher 1	FC1		156
Higher 2	FC2		202
Higher 3	FC3		248

Supplemental Material, Table S3: Number of subjects in each quartile of the variables age and birth year.

Sampling year	Age quartiles				Birth year quartiles			
	29-47	47-57	57-66	66-82	1925-1934	1934-1936	1936-1941	1941-1950
1979	42	9	0	0	14	12	14	11
1986	17	29	5	0	15	12	14	10
1994	5	18	19	3	12	10	13	10
2001	0	7	29	12	12	13	13	10
2007	0	1	13	38	15	13	13	11

Supplemental Material, Table S4: Concentrations (ng/g lipid) of 41 compounds^a analyzed in serum samples of men (N = 51, 51, 45, 48 and 52 in 1979, 1986, 1994, 2001 and 2007, respectively) in the Tromsø study. Continues on next page.

Compound	1979 N=51				1986 N=51				1994 N=45				2001 N=48				2007 N=52			
	Median (Range)	AM	% > LOD ^b	L O D ^c	Median (Range)	AM	% > LOD ^b	L O D ^c	Median (Range)	AM	% > LOD ^b	L O D ^c	Median (Range)	AM	% > LOD ^b	L O D ^c	Median (Range)	AM	% > LOD ^b	L O D ^c
<i>α</i> -HCH	3.7 (0.6-23)	4.3	100	0.4	1.8 (0.8-13)	2.2	100	0.5	- (0.1-0.8)	0.4	38	0.4	0.4 (0.1-1.2)	0.6	48	0.6	-	-	8	0.6
<i>β</i> -HCH ^d	67 (13-190)	72	100	8.4	34 (3.9-100)	40	96	8.5	13 (1.1-50)	14	79	7.8	13 (0-48)	14	67	9.5	- (1.4-25)	8.8	30	9.4
<i>γ</i> -HCH	2.2 (0.7-16)	3	79	1.7	- (0.7-4.8)	1.7	38	1.7	-	-	10	1.6	-	-	4	1.9	-	-	0	1.9
HCB	170 (34-420)	180	100	3.2	130 (71-410)	150	100	3.2	53 (31-130)	61	100	2.9	62 (20-130)	64	100	3.6	40 (15-85)	43	100	3.6
<i>t</i> -chlordane	0.4 (0.2-1.9)	0.5	53	0.5	0.6 (0.2-2.3)	0.7	63	0.5	0.3 (0.2-1)	0.5	46	0.5	0.3 (0.2-1.2)	0.5	38	0.6	-	-	17	0.6
<i>c</i> -chlordane	-	-	15	2.3	-	-	10	2.3	-	-	2	2.1	-	-	0	2.6	-	-	0	2.6
<i>oxy</i> -chlordane ^e	25 (6.5-56)	25	98	2	27 (11-100)	35	100	2	18 (9.1-49)	21	98	1.8	21 (5.9-63)	24	100	2.2	18 (4.2-53)	20	100	2.2
<i>t</i> -nonachlor	47 (5.4-150)	51	100	0.8	67 (23-230)	80	100	0.8	45 (19-130)	53	100	0.7	45 (14-170)	60	100	0.9	45 (9.5-140)	50	100	0.9
<i>c</i> -nonachlor	12 (1.1-36)	12	100	1.5	14 (5.4-55)	19	100	1.5	11 (4.5-33)	13	98	1.4	13 (3.7-40)	15	100	1.7	11 (3-35)	13	100	1.7
Mirex	6.6 (1.5-17)	7.5	98	1.7	8.9 (3.7-33)	11	100	1.6	7.3 (2.5-22)	9.2	100	1.6	8.7 (3.5-25)	9.8	100	1.6	7.5 (2.8-21)	8.6	100	1.6
Parlar No. 26	18 (2.7-77)	21	96	0.6	18 (5.4-87)	27	100	0.6	9.4 (3.2-33)	12	98	0.5	9.2 (1.5-31)	12	100	0.7	7.6 (1.9-21)	8.6	100	0.7
Parlar No. 50	34 (5.3-130)	39	96	1.7	35 (8.2-160)	52	98	1.7	21 (9.5-61)	27	98	1.6	23 (4.6-65)	28	100	2	18 (3.9-50)	20	98	1.8
<i>p,p'</i> -DDD	16 (2.5-73)	21	91	6	9.4 (2.9-67)	13	79	5.6	- (1.1-14)	4.7	23	5.2	-	-	6	6.3	-	-	6	6.3
<i>o,p'</i> -DDT	48 (1.1-87)	4	85	4	51 (1.1-45)	11	79	2.4	45 (0.3-6.5)	34	23	2.3	-	-	13	2.8	-	-	8	2.4
<i>p,p'</i> -DDT	89 (21-440)	110	98	4.7	41 (17-160)	51	100	3.2	12 (4.5-33)	13	98	3	7.7 (1.5-27)	8.5	81	3.7	3.8 (0.2-25)	5.3	60	3.3
<i>p,p'</i> -DDE	1100 (230-3400)	1200	100	4.1	800 (250-4500)	920	100	4.2	350 (100-1400)	390	100	3.7	320 (60-980)	320	100	4.8	210 (29-770)	210	100	4.6
<i>o,p'</i> -DDE	1 (0.3-5.6)	1.6	53	1.6	- (0.1-5.5)	1	38	1.2	-	-	8	1.1	-	-	0	1.4	-	-	2	1.2
PCB 18	5.4 (1.2-84)	8	85	2.6	-	-	10	2.7	-	-	0	2.4	- (0.5-6.1)	2.8	31	3	2.6 (0.5-9.1)	3.1	51	3
PCB 28/31	5.5 (1.3-43)	6.7	92	2.7	2.9 (1.1-72)	5.2	56	2.9	- (0.7-4.9)	2.3	15	2.6	- (1.2-11)	2.6	21	3.2	- (1.3-6.1)	2.7	26	3.1
PCB 33	0.8 (0.2-30)	2	58	1	-	-	17	0.8	-	-	2	0.8	-	-	19	0.9	- (0.1-2.3)	0.7	28	1
PCB 47/49	1.4 (0.5-8.4)	1.6	89	1.1	1 (0.3-73)	2.4	71	1.3	0.4 (0.2-1.4)	0.5	40	0.7	0.9 (0.2-4)	1.2	73	0.7	0.7 (0.2-2.8)	0.8	74	0.9
PCB 52	3.8 (0.9-30)	5.8	58	4.2	- (1.3-73)	5.9	42	4.6	-	-	10	3.8	-	-	15	4.7	-	-	19	4.5
PCB 99	38 (12-110)	45	100	0.9	38 (16-130)	46	100	0.9	20 (10-52)	25	100	0.7	19 (7-44)	22	100	1.1	13 (4-34)	15	100	0.9
PCB 101	6.1 (1.1-19)	7.5	94	3.4	5.1 (2-74)	8	81	3.3	2.1 (1.5-10)	3.3	50	3.1	2.3 (1.8-7)	3.1	46	3.5	- (1.2-7.7)	2.7	25	3.7
PCB 105	16 (4.4-55)	20	98	1.8	15 (5-79)	21	100	1.4	9.1 (2.5-27)	11	98	1	8.2 (1.4-25)	9.5	98	1.4	6 (1.3-17)	6.7	100	1.3
PCB 118	70 (19-230)	83	100	3.4	66 (20-330)	88	100	2.9	42 (14-120)	49	100	2.9	39 (7.9-130)	44	100	3.2	28 (6.1-82)	32	100	3.2
PCB 123	1.7 (0.1-7.1)	1.9	66	1.8	1.5 (0.1-3.6)	2.1	69	1.4	1 (0.1-3.6)	1.3	63	1	- (0-3.6)	1.2	44	1.4	- (0-2.9)	0.8	28	1.3
PCB 128	2.8 (0.2-11)	3.1	77	1.7	2.5 (0.3-14)	3.3	81	1.5	1.5 (0.3-5.6)	1.8	65	1.2	- (0.2-4.1)	1.3	33	1.6	-	-	11	1.4
PCB 138/163	270 (110-670)	310	100	3.5	280 (130-770)	350	100	3.3	180 (120-490)	210	100	3.1	170 (77-450)	190	100	3.8	120 (45-310)	140	100	4

Supplemental Material, Table S4 (cont.):

Compound	1979 N=51				1986 N=51				1994 N=45				2001 N=48				2007 N=52			
	Median (Range)	AM	% > LOD ^b	L O D ^c	Median (Range)	AM	% > LOD ^b	L O D ^c	Median (Range)	AM	% > LOD ^b	L O D ^c	Median (Range)	AM	% > LOD ^b	L O D ^c	Median (Range)	AM	% > LOD ^b	L O D ^c
PCB 141	-	-	40	2.1	-	-	23	1.8	-	-	15	1.6	-	-	10	1.9	-	-	2	2.5
PCB 149	2.6 (0.5-8.7)	3.2	85	1.9	2.2 (0.3-11)	3	71	1.7	0.7 (0.1-4.8)	1.3	44	1.4	- (0.1-3.1)	1.4	42	1.8	-	-	11	2.3
PCB 153	360 (130-910)	380	100	4.6	360 (180-1100)	450	100	4.6	250 (160-700)	290	100	4.5	240 (120-740)	260	100	5.3	170 (67-470)	200	100	5.2
PCB 156	33 (12-78)	35	100	1.2	35 (17-92)	42	100	1	23 (14-61)	27	100	0.9	24 (10-69)	26	100	1.1	19 (8-52)	21	100	1
PCB 157	6.1 (1.9-14)	6.6	98	1.1	6.9 (2.8-19)	8.2	100	0.9	4.9 (1.4-12)	5.5	96	0.8	4.9 (1.7-15)	5.6	100	1	3.8 (1.3-9.5)	4.3	100	0.9
PCB 167	11 (3.3-32)	13	100	1.1	11 (4-44)	14	100	1	7.4 (2.5-23)	8.9	100	0.8	7.1 (1.3-23)	7.9	100	1	5.7 (1-17)	6.1	100	0.9
PCB 170	82 (32-180)	87	100	1.5	89 (47-250)	110	100	1.4	63 (38-160)	72	100	1.2	59 (31-160)	66	100	1.6	48 (26-130)	53	100	1.4
PCB 180	210 (82-540)	230	100	4.1	230 (130-740)	290	100	3.9	170 (110-460)	200	100	3.9	160 (87-470)	190	100	4.6	130 (66-370)	150	100	4.6
PCB 183	21 (9.5-49)	23	100	1.1	19 (7.5-66)	25	100	1	13 (7-37)	15	100	0.9	10 (3.9-32)	12	100	1.1	7.5 (1.9-23)	8.5	100	1.1
PCB 187	64 (22-140)	67	100	1.3	66 (31-230)	81	100	1.2	48 (29-120)	54	100	1	43 (24-110)	49	100	1.3	35 (15-88)	39	100	1.2
PCB 189	3.7 (1.2-8.1)	4	98	1.2	4 (1.9-13)	5	100	1.1	3.2 (1.4-8.2)	3.6	94	0.9	3.3 (1.3-9)	3.5	100	1.2	2.5 (0.8-7)	2.7	92	1.2
PCB 194	24 (9.1-79)	27	100	1.4	28 (15-130)	34	100	1.3	22 (14-78)	26	100	1.1	20 (11-55)	24	100	1.5	18 (8.7-50)	20	100	1.3


^aFor compound abbreviations, see Table S1. Censored summary statistics are presented for compounds with detection frequencies less than 90%: α -, β -, γ -HCH, *t*-chlordane, PCB congeners 18, 28/31, 33, 47/49, 52, 101, 123, 128, 149, *p,p'*-DDD, *o,p'*-DDT and *o,p'*-DDE.

^b% > LOD = Percentage of sample in which analyte was detected.

^cLOD = Limit of detection (average of sample-specific LODs).

^dPresented concentrations reflect the subtraction of average blank values of 107 pg before calculating wet-weight concentrations.

^ePresented concentrations reflect the subtraction of average blank values of 43 pg before calculating wet-weight concentration.




Supplemental Material, Figure S1: Model predictions of concentrations (ng/g lipid) of PCBs


118, 138, 153, and 180 in a male 1935 birth cohort shown along with median measured

concentrations in 1979, 1986, 1994, 2001 and 2007. Separate predictions for average Norwegian

fish consumption (FC_{avr}) and three categories of higher fish intake rates are presented (FC1-FC3).



Supplemental Material, Figure S2: Model predictions of concentrations (ng/g lipid) of PCB-153 are displayed for the 1930, 1935, 1940 and 1945 male birth cohorts. All cohorts are assumed to have equal fish consumption (FC2).



Supplemental Material, Figure S3: Remaining plots of graphical APC examination in PCB-153 concentrations. This figure complements Figure 4 in the main text. A and D depict time-lag variation among age groups according to sampling period, B and E time-lag variation among age groups according to birth cohort group, and C and F cross-sectional variation among sampling periods according to birth cohort group.

Supplemental Material, References

- Alexander J, Frøyland L, Hemre G, Koster Jacobsen B, Lund E, Meltzer H. 2006. Et helhetssyn på fisk og annen sjømat i norsk kosthold. [in Norwegian] Oslo, Norway. Norwegian Scientific Committee for Food Safety. Available from: www.vkm.no/dav/a2805d6a8c.pdf
- Bergsten C. 2004. Fish and game study, part B. (The consumption of foods that may be important when assessing the dietary intake of mercury, cadmium and PCB/dioxins, with a focus on population groups living on the coast and in the inland of Norway). [in Norwegian] Oslo, Norway. Norwegian Food Safety Authority. Available from: www.mattilsynet.no/mattilsynet/multimedia/archive/00016/Fisk_og_vilt__Fish_a_16664a.pdf
- Czub G, McLachlan MS. 2004. A food chain model to predict the levels of lipophilic organic contaminants in humans. *Environ Toxicol Chem* 23(10): 2356-2366.
- Johansson L, Solvoll KN. 1999. Norkost 1997. Landsomfattende kostholdsundersøkelse blant menn og kvinner i alderen 16-79 år. [in Norwegian] Report No.: 2/1999. Oslo, Norway. National Council on Nutrition and Physical Activity. Available from: www.helsedirektoratet.no/folkehelse/ertering/tall-og-undersokelser/Documents/norkost-1997.pdf
- Norwegian Directorate of Health. 2010. Utviklingen i norsk kosthold. Matforsyningsstatistikk og Forbruksundersøkelser. [in Norwegian] Report No.: IS-1873. Oslo, Norway. Available from: <http://www.helsedirektoratet.no/publikasjoner/utviklingen-i-norsk-kosthold-2010-stor-utgave/Publikasjoner/utviklingen-i-norsk-kosthold2010-stor-utgave.pdf>